Home › Funds › ADAR1 Capital Management, LLC › PTGX
ADAR1 Capital Management, LLC position in PTGX
PROTAGONIST THERAPEUTICS INC · Health Care
ADAR1 Capital Management, LLC reported holding 960,863 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$117.8M, representing 6.52% of its reported portfolio and ranking #1 among its reported holdings. ADAR1 Capital Management, LLC has disclosed PTGX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ADAR1 Capital Management, LLC's PTGX position evolved
ADAR1 Capital Management, LLC first disclosed a stake in PTGX in Q4 2023 at 200,859 shares (US$4.6M). The position peaked in Q2 2026 at 960,863 shares, worth US$117.8M. Across 11 filings, ADAR1 Capital Management, LLC increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 960,863 shares valued at US$117.8M — a reduction of -33,256 shares quarter over quarter.. Notable position changes include a 291% increase in Q1 2024 (shares rose 20% over the following quarter), a 104% increase in Q2 2024 (shares rose 30% over the following quarter), a 612% increase in Q1 2025 (shares rose 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 200.86K | $4.61M | New |
| Q1 2024 | 785.65K | $22.73M | Add |
| Q2 2024 | 1.60M | $55.58M | Add |
| Q3 2024 | 981.29K | $44.16M | Reduce |
| Q4 2024 | 132.00K | $5.10M | Reduce |
| Q1 2025 | 939.67K | $45.44M | Add |
| Q2 2025 | 948.07K | $52.40M | Add |
| Q3 2025 | 989.18K | $65.71M | Add |
| Q4 2025 | 1.05M | $91.63M | Add |
| Q1 2026 | 994.12K | $104.78M | Reduce |
| Q2 2026 | 960.86K | $117.78M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PTGX and 13F data
PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in PTGX — the largest reported positions include Farallon Capital Management (US$778.2M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$778.2M), RTW INVESTMENTS, LP (US$620.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PTGX
- Farallon Capital Management 6.35M sh · $778.25M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 6.35M sh · $778.25M · Q2 2026
- RTW INVESTMENTS, LP 5.06M sh · $620.40M · Q2 2026
- JOHNSON & JOHNSON 2.45M sh · $300.22M · Q2 2026
- Woodline Partners LP 1.41M sh · $173.35M · Q2 2026
- PERCEPTIVE ADVISORS LLC 981.88K sh · $120.36M · Q2 2026
- Hood River Capital Management LLC 882.74K sh · $108.21M · Q2 2026
- 683 Capital Management, LLC 290.00K sh · $35.55M · Q2 2026
- Eagle Health Investments LP 248.32K sh · $30.44M · Q2 2026
More on ADAR1 Capital Management, LLC
FAQ
How long has ADAR1 Capital Management, LLC held PTGX?
ADAR1 Capital Management, LLC has disclosed PTGX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.
What is ADAR1 Capital Management, LLC's current position in PTGX?
As of Q2 2026, ADAR1 Capital Management, LLC holds 960.86K shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $117.78M, representing 6.52% of its reported portfolio and ranking #1.
Has ADAR1 Capital Management, LLC been buying or selling PTGX?
In the latest 13F filing (Q2 2026), ADAR1 Capital Management, LLC reduced its position in PTGX. The position peaked in Q2 2026 at 960.86K shares.
Which other funds hold PTGX?
Other major institutional holders of PTGX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., RTW INVESTMENTS, LP, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.